AbCellera Biologics Inc. ABCL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$143.96M+14.2% | -$146.41M+10.1% | -$171.68M+2.3% | -$165.67M-8.1% | -$167.87M-14.3% | ||
| $19.9M+45.2% | $18.39M+47.7% | $15.31M+7.5% | $14.81M+9.4% | $13.71M+4.3% | ||
| $53.02M-18.4% | $55.79M-17.4% | $58.11M-15.5% | $61.38M-9.1% | $64.96M-1.8% | ||
| -$2.54M-121% | $3.46M-67.5% | $4.33M+1,690% | $3.41M+144% | $12.1M+175% | ||
| -$8.09M+52.1% | -$17.15M-188% | -$19.02M-27.3% | -$20.88M+3.4% | -$16.88M+18.5% | ||
| $3.17M— | $3.33M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$30.41M-660% | -$29.84M-549% | -$4.43M+36.0% | $5.02M+208% | $5.43M-86.4% | ||
| —— | —— | —— | —— | —— | ||
| $7.19M+30.8% | $6.65M+8.1% | $6.19M-3.1% | $5.58M-16.6% | $5.5M-19.3% | ||
| $41.39M-28.2% | $55.62M-26.0% | $36.82M-43.1% | $53.21M-5.1% | $57.68M-20.4% | ||
| —— | $30.11M— | $22.58M— | $15.06M— | $7.53M— | ||
| -$153.26M-95.5% | -$131.3M-20.9% | -$104.55M+13.0% | -$80.84M+11.5% | -$78.4M— | ||
| $35.97M-44.6% | $42.77M-45.4% | $48.56M-37.1% | $58.15M-26.4% | $64.89M-24.6% | ||
| —— | -$33.27M— | -$24.95M— | -$16.63M— | -$8.32M— | ||
| $54.73M-45.0% | $87.75M-27.7% | $48.32M-21.3% | $15.53M-65.4% | $99.43M+339% | ||
| —— | —— | —— | —— | $15.91M+16.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$43.48M+5.0% | -$55.88M-77.8% | $35.69M+151% | ||
| $3.7M— | $3.7M— | —— | —— | —— | ||
| $19.9M+45.2% | $18.39M+47.7% | $15.31M+7.5% | $14.81M+9.4% | $13.71M+4.3% | ||
| —— | $30.11M— | $22.58M— | $15.06M— | $7.53M— | ||
| —— | -$4.53M-107% | $12.79M-74.7% | $30.1M-17.2% | $47.41M+114% | ||
| $4.77M+122% | $3.64M+111% | -$462K+98.8% | -$12.53M+62.8% | -$21.47M+53.6% | ||
| —— | —— | —— | —— | —— | ||
| -$8.09M+52.1% | -$17.15M-188% | -$19.02M-27.3% | -$20.88M+3.4% | -$16.88M+18.5% | ||
| $7.19M+30.8% | $6.65M+8.1% | $6.19M-3.1% | $5.58M-16.6% | $5.5M-19.3% | ||
| $3.17M— | $3.33M— | —— | —— | —— | ||
| —— | -$33.27M— | -$24.95M— | -$16.63M— | -$8.32M— | ||
| $9.71M— | $17.09M— | —— | —— | —— | ||
| $21.69M-26.6% | $21.34M-40.2% | $13.92M-64.7% | $22.41M-40.0% | $29.56M-0.8% | ||
| —— | $29.73M+120% | $25.67M+97.2% | $21.61M+72.3% | $17.56M+45.5% | ||
| —— | —— | —— | —— | —— | ||
| -$189.23M-32.1% | -$174.07M+6.9% | -$153.11M+22.4% | -$138.99M+18.4% | -$143.29M-12.3% | ||
| -$189.23M-32.1% | -$174.07M+6.9% | -$153.11M+22.4% | -$138.99M+18.4% | -$143.29M-12.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does AbCellera Biologics Inc. generate?
- AbCellera Biologics Inc. (ABCL) generated -$153.3M in operating cash flow over the trailing twelve months.
- What is AbCellera Biologics Inc.'s free cash flow?
- After $36.0M of capital expenditures, AbCellera Biologics Inc.'s free cash flow was -$189.2M over the trailing twelve months, down 32.1% year over year.
- Where does AbCellera Biologics Inc.'s cash flow data come from?
- Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
